Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase ? trial

Autor: Perez-Garcia J, Llombart-Cussac A, G Cortes M, Curigliano G, Lopez-Miranda E, Alonso J, Bermejo B, Calvo L, Caranana V, de la Cruz Sanchez S, M Vazquez R, Prat A, R Borrego M, Sampayo-Cordero M, Segui-Palmer M, Soberino J, Malfettone A, Schmid P, Cortes J

Publikováno v: European journal of cancer (Oxford, England : 1990)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

BACKGROUND: Pembrolizumab has modest activity if used in patients with hormone-receptor-positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::66e1dbb7eb69cecc82b1ca064fca9e9c
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15700